{"title":"在筛查食管鳞状细胞癌时是否可以省略鲁戈尔色内镜检查?","authors":"Tomohiro Kadota, Tomonori Yano","doi":"10.1111/den.14873","DOIUrl":null,"url":null,"abstract":"<p>The development of multiple metachronous cancers in the remaining esophagus after treatment of esophageal squamous cell carcinoma (ESCC) is a long-term management problem. The annual incidence of multiple metachronous cancers, especially after endoscopic resection, is approximately 10% per year.<span><sup>1</sup></span> In particular, the grade according to the number of Lugol-voiding lesions (LVLs) per endoscopic view has been reported to stratify the risk.<span><sup>1</sup></span> Lugol chromoendoscopy (LCE) is useful for the detection of ESCC and is the standard practice worldwide. However, with the advancement of image-enhanced endoscopy (IEE), narrow-band imaging (NBI) has proven to be significantly superior to white-light imaging (WLI) in detecting ESCC<span><sup>2</sup></span> and is widely used in routine clinical practice. Blue-light imaging (BLI) is considered a modality similar to NBI in the esophagus. As the image quality of IEE has improved, the possibility of replacing LCE with NBI and BLI has been discussed. To date, a meta-analysis using expert-focused studies has shown that NBI has a sensitivity comparable to that of LCE but superior specificity in identifying high-grade dysplasia and/or squamous cell carcinoma of the esophagus.<span><sup>3</sup></span> In addition, as a prospective randomized controlled trial that included nonexperts revealed the higher specificity of NBI, the latest European guidelines recommend narrow light observation as an alternative to LCE for detecting ESCC.<span><sup>4</sup></span> However, additional LCE was proposed to improve the detection of synchronous lesions, which were easily missed by the nonexperts in this trial; thus, the positioning of LCE and NBI is controversial.</p><p>In this issue of <i>Digestive Endoscopy</i>, Ogata <i>et al</i>.<span><sup>5</sup></span> conducted a post hoc analysis of a multicenter randomized controlled trial that compared the diagnostic ability of BLI and linked-color imaging for ESCC in patients at high risk for ESCC in expert settings. In this study, the authors evaluated the diagnostic abilities of BLI and LCE after BLI. Finally, BLI had a significantly lower sensitivity (83.7% vs. 100.0%) and higher specificity (88.2% vs. 81.2%) and accuracy (87.8% vs. 82.5%) than LCE following BLI in the per-patient analysis. In contrast, BLI had a slightly lower detection rate (5.9% vs. 7.0%) and a significantly higher miss rate (18.4% vs. 4.1%) than LCE following BLI. Because the order of examination is usually IEE observation followed by chromoendoscopy, it is difficult to compare the true diagnostic abilities of digital imaging and chromoendoscopy. The strength of this study may be its characterization of BLI and LCE in the diagnosis of superficial ESCC and its suggestion that these may complement each other. Ogata <i>et al</i>. analyzed the characteristics of lesions missed using BLI. Although flat lesions tended to be more frequent in missed lesions than in detected lesions, all lesions missed by BLI were confined to the epithelium/lamina propria mucosa (pT1a-EP/LPM). Other reports similarly reported that many of the lesions missed by NBI/BLI were flat<span><sup>6, 7</sup></span> and most were pT1a-EP/LPM lesions, but some were confined to the muscularis mucosae or submucosa.<span><sup>6</sup></span> The results by LVL grade showed that the proportion of LVL grade A was low for both BLI-detected and BLI-missed lesions (2.4% and 0.0%, respectively), whereas the proportion of grade C was higher (63.4% and 88.9%, respectively). These results may provide insights into the use of BLI and LCE, such as omitting LCE in LVL grade A cases.</p><p>Subsequently, Ogata <i>et al</i>. attempted to logically explain their results by objectively comparing BLI and LCE using color difference analysis between cancerous and noncancerous regions. This showed a higher color difference in LCE than in BLI, which supports the results of higher sensitivity in LCE following BLI and is compatible with our impression during examinations.</p><p>Furthermore, 19 of the 50 lesions detected in this study had a history of radiotherapy for ESCC, 16 of which were detected by BLI and the remainder were missed by BLI. Chemoradiotherapy (CRT) for ESCC has become widely used as a curative strategy, and the importance of surveillance after CRT for ESCC is increasing. However, differential diagnosis with local residues, recurrence, metachronous ESCC, and usual post-CRT sequelae such as mucositis or fibrosis remains an unmet issue in the endoscopic observation for patients after CRT. This is because unspecified LVLs similar to ESCC can be shown in the esophageal mucosa after CRT. Asada-Hirayama <i>et al</i>. reported that NBI with magnification showed equal sensitivity and significantly higher PPV (85.7% vs. 8.3%) compared to LCE in detecting ESCC or high-grade intraepithelial neoplasia in the patients with a history of CRT.<span><sup>8</sup></span> Therefore, IEE may have a potential to detect metachronous ESCC efficiently in patients after CRT.</p><p>In recent years, artificial intelligence (AI) has been developed for endoscopy. Using AI assistance in diagnosing of ESCC has improved the diagnostic accuracy of both novice and expert endoscopists. Additionally, in a large multicenter, tandem randomized controlled trial of more than 10,000 cases, it was reported that the AI-first group reduced, but without reaching significance, the per-lesion miss rate of ESCC and precancerous lesions (1.7% vs. 6.7%) and improved the detection rate (1.8% vs. 1.3%) compared with the routine-first group.<span><sup>9</sup></span> The study involved endoscopists from different types of institutions with a variety of experience and skills; therefore, the AI system is expected to play a role as a valuable auxiliary tool to facilitate the homogenization of ESCC diagnosis for endoscopists at all levels. Because this study specified observations using WLI and NBI, and LCE was used in only approximately 2% of cases, the addition of LCE was not analyzed. On the other hand, AI systems using WLI and NBI imaging that predict multiple LVLs have also been reported. Future research may lead to the development of AI technology that surpasses LCE.</p><p>Although LCE is known to be a reliable method for the detection of ESCC, it is problematic in terms of safety and symptoms such as heartburn, chest pain, and nausea caused by the sprayed potassium iodide solution, as well as a significantly longer examination time. Therefore, attempts have been made to omit LCE. Although studies within a single endoscopy session often focus on the diagnostic ability of the lesion and how much is missed, these studies are strongly associated with surveillance methods and the true benefit to the patient is debatable. If the surveillance interval can be shortened, it may not matter if some cEP/LPM lesions are missed; however, if the surveillance interval is long, the number of missed cancers should be minimized. Of course, lesions deeper than cMM/SM1 (tumor invasion of the muscularis mucosae or submucosa ≤200 μm) cannot be missed regardless of the surveillance interval, and if they are missed, the risk of lymph node metastasis is a concern and may affect the quality of life and prognosis of the patient. Current Japanese guidelines recommend endoscopy at least once per year,<span><sup>10</sup></span> whereas endoscopy every 3 to 6 months is recommended in Europe,<span><sup>4</sup></span> and there are currently no uniform recommendations for surveillance. Furthermore, surveillance methods should be considered according to the risk of multiple metachronous ESCC, such as the LVL grade. Thus, a prospective randomized trial that includes surveillance methods and surveillance intervals, taking LVL grade into account, is desirable.</p><p>This study provides useful insights into routine practice in this field and raises interesting questions regarding ESCC detection. It is also important to understand the weaknesses of BLI and NBI observations and decide on the observation method on a case-by-case basis, depending on the risk of multiple metachronous ESCC and the surveillance interval. Further studies are required to determine appropriate surveillance methods.</p><p>Author T.Y. is an Associate Editor of <i>Digestive Endoscopy</i> and T.Y. receives research grants from Fujifilm and Olympus outside of this work. T.K. declares no conflict of interest for this article.</p><p>None.</p>","PeriodicalId":159,"journal":{"name":"Digestive Endoscopy","volume":"36 10","pages":"1127-1129"},"PeriodicalIF":5.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.14873","citationCount":"0","resultStr":"{\"title\":\"Is Lugol chromoendoscopy omissible in screening for esophageal squamous cell carcinoma?\",\"authors\":\"Tomohiro Kadota, Tomonori Yano\",\"doi\":\"10.1111/den.14873\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The development of multiple metachronous cancers in the remaining esophagus after treatment of esophageal squamous cell carcinoma (ESCC) is a long-term management problem. The annual incidence of multiple metachronous cancers, especially after endoscopic resection, is approximately 10% per year.<span><sup>1</sup></span> In particular, the grade according to the number of Lugol-voiding lesions (LVLs) per endoscopic view has been reported to stratify the risk.<span><sup>1</sup></span> Lugol chromoendoscopy (LCE) is useful for the detection of ESCC and is the standard practice worldwide. However, with the advancement of image-enhanced endoscopy (IEE), narrow-band imaging (NBI) has proven to be significantly superior to white-light imaging (WLI) in detecting ESCC<span><sup>2</sup></span> and is widely used in routine clinical practice. Blue-light imaging (BLI) is considered a modality similar to NBI in the esophagus. As the image quality of IEE has improved, the possibility of replacing LCE with NBI and BLI has been discussed. To date, a meta-analysis using expert-focused studies has shown that NBI has a sensitivity comparable to that of LCE but superior specificity in identifying high-grade dysplasia and/or squamous cell carcinoma of the esophagus.<span><sup>3</sup></span> In addition, as a prospective randomized controlled trial that included nonexperts revealed the higher specificity of NBI, the latest European guidelines recommend narrow light observation as an alternative to LCE for detecting ESCC.<span><sup>4</sup></span> However, additional LCE was proposed to improve the detection of synchronous lesions, which were easily missed by the nonexperts in this trial; thus, the positioning of LCE and NBI is controversial.</p><p>In this issue of <i>Digestive Endoscopy</i>, Ogata <i>et al</i>.<span><sup>5</sup></span> conducted a post hoc analysis of a multicenter randomized controlled trial that compared the diagnostic ability of BLI and linked-color imaging for ESCC in patients at high risk for ESCC in expert settings. In this study, the authors evaluated the diagnostic abilities of BLI and LCE after BLI. Finally, BLI had a significantly lower sensitivity (83.7% vs. 100.0%) and higher specificity (88.2% vs. 81.2%) and accuracy (87.8% vs. 82.5%) than LCE following BLI in the per-patient analysis. In contrast, BLI had a slightly lower detection rate (5.9% vs. 7.0%) and a significantly higher miss rate (18.4% vs. 4.1%) than LCE following BLI. Because the order of examination is usually IEE observation followed by chromoendoscopy, it is difficult to compare the true diagnostic abilities of digital imaging and chromoendoscopy. The strength of this study may be its characterization of BLI and LCE in the diagnosis of superficial ESCC and its suggestion that these may complement each other. Ogata <i>et al</i>. analyzed the characteristics of lesions missed using BLI. Although flat lesions tended to be more frequent in missed lesions than in detected lesions, all lesions missed by BLI were confined to the epithelium/lamina propria mucosa (pT1a-EP/LPM). Other reports similarly reported that many of the lesions missed by NBI/BLI were flat<span><sup>6, 7</sup></span> and most were pT1a-EP/LPM lesions, but some were confined to the muscularis mucosae or submucosa.<span><sup>6</sup></span> The results by LVL grade showed that the proportion of LVL grade A was low for both BLI-detected and BLI-missed lesions (2.4% and 0.0%, respectively), whereas the proportion of grade C was higher (63.4% and 88.9%, respectively). These results may provide insights into the use of BLI and LCE, such as omitting LCE in LVL grade A cases.</p><p>Subsequently, Ogata <i>et al</i>. attempted to logically explain their results by objectively comparing BLI and LCE using color difference analysis between cancerous and noncancerous regions. This showed a higher color difference in LCE than in BLI, which supports the results of higher sensitivity in LCE following BLI and is compatible with our impression during examinations.</p><p>Furthermore, 19 of the 50 lesions detected in this study had a history of radiotherapy for ESCC, 16 of which were detected by BLI and the remainder were missed by BLI. Chemoradiotherapy (CRT) for ESCC has become widely used as a curative strategy, and the importance of surveillance after CRT for ESCC is increasing. However, differential diagnosis with local residues, recurrence, metachronous ESCC, and usual post-CRT sequelae such as mucositis or fibrosis remains an unmet issue in the endoscopic observation for patients after CRT. This is because unspecified LVLs similar to ESCC can be shown in the esophageal mucosa after CRT. Asada-Hirayama <i>et al</i>. reported that NBI with magnification showed equal sensitivity and significantly higher PPV (85.7% vs. 8.3%) compared to LCE in detecting ESCC or high-grade intraepithelial neoplasia in the patients with a history of CRT.<span><sup>8</sup></span> Therefore, IEE may have a potential to detect metachronous ESCC efficiently in patients after CRT.</p><p>In recent years, artificial intelligence (AI) has been developed for endoscopy. Using AI assistance in diagnosing of ESCC has improved the diagnostic accuracy of both novice and expert endoscopists. Additionally, in a large multicenter, tandem randomized controlled trial of more than 10,000 cases, it was reported that the AI-first group reduced, but without reaching significance, the per-lesion miss rate of ESCC and precancerous lesions (1.7% vs. 6.7%) and improved the detection rate (1.8% vs. 1.3%) compared with the routine-first group.<span><sup>9</sup></span> The study involved endoscopists from different types of institutions with a variety of experience and skills; therefore, the AI system is expected to play a role as a valuable auxiliary tool to facilitate the homogenization of ESCC diagnosis for endoscopists at all levels. Because this study specified observations using WLI and NBI, and LCE was used in only approximately 2% of cases, the addition of LCE was not analyzed. On the other hand, AI systems using WLI and NBI imaging that predict multiple LVLs have also been reported. Future research may lead to the development of AI technology that surpasses LCE.</p><p>Although LCE is known to be a reliable method for the detection of ESCC, it is problematic in terms of safety and symptoms such as heartburn, chest pain, and nausea caused by the sprayed potassium iodide solution, as well as a significantly longer examination time. Therefore, attempts have been made to omit LCE. Although studies within a single endoscopy session often focus on the diagnostic ability of the lesion and how much is missed, these studies are strongly associated with surveillance methods and the true benefit to the patient is debatable. If the surveillance interval can be shortened, it may not matter if some cEP/LPM lesions are missed; however, if the surveillance interval is long, the number of missed cancers should be minimized. Of course, lesions deeper than cMM/SM1 (tumor invasion of the muscularis mucosae or submucosa ≤200 μm) cannot be missed regardless of the surveillance interval, and if they are missed, the risk of lymph node metastasis is a concern and may affect the quality of life and prognosis of the patient. Current Japanese guidelines recommend endoscopy at least once per year,<span><sup>10</sup></span> whereas endoscopy every 3 to 6 months is recommended in Europe,<span><sup>4</sup></span> and there are currently no uniform recommendations for surveillance. Furthermore, surveillance methods should be considered according to the risk of multiple metachronous ESCC, such as the LVL grade. Thus, a prospective randomized trial that includes surveillance methods and surveillance intervals, taking LVL grade into account, is desirable.</p><p>This study provides useful insights into routine practice in this field and raises interesting questions regarding ESCC detection. It is also important to understand the weaknesses of BLI and NBI observations and decide on the observation method on a case-by-case basis, depending on the risk of multiple metachronous ESCC and the surveillance interval. Further studies are required to determine appropriate surveillance methods.</p><p>Author T.Y. is an Associate Editor of <i>Digestive Endoscopy</i> and T.Y. receives research grants from Fujifilm and Olympus outside of this work. T.K. declares no conflict of interest for this article.</p><p>None.</p>\",\"PeriodicalId\":159,\"journal\":{\"name\":\"Digestive Endoscopy\",\"volume\":\"36 10\",\"pages\":\"1127-1129\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/den.14873\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digestive Endoscopy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/den.14873\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive Endoscopy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/den.14873","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
食管鳞状细胞癌(ESCC)治疗后,残余食管中会出现多发性间变性癌症,这是一个长期管理问题。尤其是在内镜切除术后,每年多发并发症的发生率约为 10%。1 有报道称,根据每个内镜视野中的鲁戈尔空洞病变(LVL)数量进行分级可对风险进行分层。然而,随着图像增强内镜(IEE)的发展,窄带成像(NBI)被证明在检测 ESCC 方面明显优于白光成像(WLI)2 ,并被广泛应用于常规临床实践中。蓝光成像(BLI)被认为是在食管中与 NBI 相似的一种模式。随着 IEE 图像质量的提高,人们开始讨论用 NBI 和 BLI 取代 LCE 的可能性。迄今为止,一项以专家为重点的荟萃分析显示,NBI 的灵敏度与 LCE 相当,但在鉴别食管高级别发育不良和/或鳞状细胞癌方面具有更高的特异性。3 此外,由于一项包括非专家在内的前瞻性随机对照试验显示 NBI 具有更高的特异性,最新的欧洲指南建议将窄光观察作为检测 ESCC 的 LCE 替代方法。在本期《消化内镜》杂志上,Ogata 等人5 对一项多中心随机对照试验进行了事后分析,该试验比较了 BLI 和联动彩色成像在专家环境下对 ESCC 高危患者的诊断能力。在这项研究中,作者评估了 BLI 和 LCE 在 BLI 之后的诊断能力。最后,在对每位患者的分析中,BLI 的灵敏度(83.7% 对 100.0%)明显低于 LCE,而特异性(88.2% 对 81.2%)和准确性(87.8% 对 82.5%)则高于 LCE。相比之下,BLI 的检出率(5.9% 对 7.0%)略低,而漏检率(18.4% 对 4.1%)则明显高于 BLI 后的 LCE。由于检查顺序通常是先观察 IEE,再进行色内镜检查,因此很难比较数字成像和色内镜检查的真正诊断能力。这项研究的优势可能在于它描述了 BLI 和 LCE 在诊断浅表 ESCC 中的特点,并提出这两种方法可以互补。Ogata 等人分析了使用 BLI 时漏诊病灶的特征。虽然扁平病变在漏诊病变中的发生率往往高于检测到的病变,但 BLI 漏诊的所有病变均局限于上皮/固有膜粘膜(pT1a-EP/LPM)。6 按 LVL 分级的结果显示,在 BLI 检测到的病变和 BLI 漏检的病变中,LVL A 级的比例较低(分别为 2.4% 和 0.0%),而 C 级的比例较高(分别为 63.4% 和 88.9%)。随后,Ogata 等人试图用癌变和非癌变区域的色差分析来客观比较 BLI 和 LCE,从而从逻辑上解释他们的结果。此外,在本研究检测出的 50 个病灶中,有 19 个病灶曾因 ESCC 接受过放疗,其中 16 个病灶被 BLI 检测出,其余病灶则被 BLI 遗漏。ESCC的化疗放疗(CRT)作为一种根治性策略已被广泛应用,ESCC化疗放疗后监测的重要性也与日俱增。然而,与局部残留物、复发、晚期 ESCC 以及通常的 CRT 后遗症(如粘膜炎或纤维化)的鉴别诊断仍然是 CRT 后患者内镜观察中尚未解决的问题。这是因为 CRT 后食管粘膜可能会出现类似 ESCC 的不明 LVL。Asada-Hirayama 等人报告说,与 LCE 相比,放大的 NBI 在检测有 CRT 病史的患者的 ESCC 或高级别上皮内瘤变方面显示出相同的灵敏度和明显更高的 PPV(85.7% 对 8.3%)。近年来,人工智能(AI)已被开发用于内窥镜检查,利用人工智能辅助诊断 ESCC 提高了内窥镜新手和专家的诊断准确性。
Is Lugol chromoendoscopy omissible in screening for esophageal squamous cell carcinoma?
The development of multiple metachronous cancers in the remaining esophagus after treatment of esophageal squamous cell carcinoma (ESCC) is a long-term management problem. The annual incidence of multiple metachronous cancers, especially after endoscopic resection, is approximately 10% per year.1 In particular, the grade according to the number of Lugol-voiding lesions (LVLs) per endoscopic view has been reported to stratify the risk.1 Lugol chromoendoscopy (LCE) is useful for the detection of ESCC and is the standard practice worldwide. However, with the advancement of image-enhanced endoscopy (IEE), narrow-band imaging (NBI) has proven to be significantly superior to white-light imaging (WLI) in detecting ESCC2 and is widely used in routine clinical practice. Blue-light imaging (BLI) is considered a modality similar to NBI in the esophagus. As the image quality of IEE has improved, the possibility of replacing LCE with NBI and BLI has been discussed. To date, a meta-analysis using expert-focused studies has shown that NBI has a sensitivity comparable to that of LCE but superior specificity in identifying high-grade dysplasia and/or squamous cell carcinoma of the esophagus.3 In addition, as a prospective randomized controlled trial that included nonexperts revealed the higher specificity of NBI, the latest European guidelines recommend narrow light observation as an alternative to LCE for detecting ESCC.4 However, additional LCE was proposed to improve the detection of synchronous lesions, which were easily missed by the nonexperts in this trial; thus, the positioning of LCE and NBI is controversial.
In this issue of Digestive Endoscopy, Ogata et al.5 conducted a post hoc analysis of a multicenter randomized controlled trial that compared the diagnostic ability of BLI and linked-color imaging for ESCC in patients at high risk for ESCC in expert settings. In this study, the authors evaluated the diagnostic abilities of BLI and LCE after BLI. Finally, BLI had a significantly lower sensitivity (83.7% vs. 100.0%) and higher specificity (88.2% vs. 81.2%) and accuracy (87.8% vs. 82.5%) than LCE following BLI in the per-patient analysis. In contrast, BLI had a slightly lower detection rate (5.9% vs. 7.0%) and a significantly higher miss rate (18.4% vs. 4.1%) than LCE following BLI. Because the order of examination is usually IEE observation followed by chromoendoscopy, it is difficult to compare the true diagnostic abilities of digital imaging and chromoendoscopy. The strength of this study may be its characterization of BLI and LCE in the diagnosis of superficial ESCC and its suggestion that these may complement each other. Ogata et al. analyzed the characteristics of lesions missed using BLI. Although flat lesions tended to be more frequent in missed lesions than in detected lesions, all lesions missed by BLI were confined to the epithelium/lamina propria mucosa (pT1a-EP/LPM). Other reports similarly reported that many of the lesions missed by NBI/BLI were flat6, 7 and most were pT1a-EP/LPM lesions, but some were confined to the muscularis mucosae or submucosa.6 The results by LVL grade showed that the proportion of LVL grade A was low for both BLI-detected and BLI-missed lesions (2.4% and 0.0%, respectively), whereas the proportion of grade C was higher (63.4% and 88.9%, respectively). These results may provide insights into the use of BLI and LCE, such as omitting LCE in LVL grade A cases.
Subsequently, Ogata et al. attempted to logically explain their results by objectively comparing BLI and LCE using color difference analysis between cancerous and noncancerous regions. This showed a higher color difference in LCE than in BLI, which supports the results of higher sensitivity in LCE following BLI and is compatible with our impression during examinations.
Furthermore, 19 of the 50 lesions detected in this study had a history of radiotherapy for ESCC, 16 of which were detected by BLI and the remainder were missed by BLI. Chemoradiotherapy (CRT) for ESCC has become widely used as a curative strategy, and the importance of surveillance after CRT for ESCC is increasing. However, differential diagnosis with local residues, recurrence, metachronous ESCC, and usual post-CRT sequelae such as mucositis or fibrosis remains an unmet issue in the endoscopic observation for patients after CRT. This is because unspecified LVLs similar to ESCC can be shown in the esophageal mucosa after CRT. Asada-Hirayama et al. reported that NBI with magnification showed equal sensitivity and significantly higher PPV (85.7% vs. 8.3%) compared to LCE in detecting ESCC or high-grade intraepithelial neoplasia in the patients with a history of CRT.8 Therefore, IEE may have a potential to detect metachronous ESCC efficiently in patients after CRT.
In recent years, artificial intelligence (AI) has been developed for endoscopy. Using AI assistance in diagnosing of ESCC has improved the diagnostic accuracy of both novice and expert endoscopists. Additionally, in a large multicenter, tandem randomized controlled trial of more than 10,000 cases, it was reported that the AI-first group reduced, but without reaching significance, the per-lesion miss rate of ESCC and precancerous lesions (1.7% vs. 6.7%) and improved the detection rate (1.8% vs. 1.3%) compared with the routine-first group.9 The study involved endoscopists from different types of institutions with a variety of experience and skills; therefore, the AI system is expected to play a role as a valuable auxiliary tool to facilitate the homogenization of ESCC diagnosis for endoscopists at all levels. Because this study specified observations using WLI and NBI, and LCE was used in only approximately 2% of cases, the addition of LCE was not analyzed. On the other hand, AI systems using WLI and NBI imaging that predict multiple LVLs have also been reported. Future research may lead to the development of AI technology that surpasses LCE.
Although LCE is known to be a reliable method for the detection of ESCC, it is problematic in terms of safety and symptoms such as heartburn, chest pain, and nausea caused by the sprayed potassium iodide solution, as well as a significantly longer examination time. Therefore, attempts have been made to omit LCE. Although studies within a single endoscopy session often focus on the diagnostic ability of the lesion and how much is missed, these studies are strongly associated with surveillance methods and the true benefit to the patient is debatable. If the surveillance interval can be shortened, it may not matter if some cEP/LPM lesions are missed; however, if the surveillance interval is long, the number of missed cancers should be minimized. Of course, lesions deeper than cMM/SM1 (tumor invasion of the muscularis mucosae or submucosa ≤200 μm) cannot be missed regardless of the surveillance interval, and if they are missed, the risk of lymph node metastasis is a concern and may affect the quality of life and prognosis of the patient. Current Japanese guidelines recommend endoscopy at least once per year,10 whereas endoscopy every 3 to 6 months is recommended in Europe,4 and there are currently no uniform recommendations for surveillance. Furthermore, surveillance methods should be considered according to the risk of multiple metachronous ESCC, such as the LVL grade. Thus, a prospective randomized trial that includes surveillance methods and surveillance intervals, taking LVL grade into account, is desirable.
This study provides useful insights into routine practice in this field and raises interesting questions regarding ESCC detection. It is also important to understand the weaknesses of BLI and NBI observations and decide on the observation method on a case-by-case basis, depending on the risk of multiple metachronous ESCC and the surveillance interval. Further studies are required to determine appropriate surveillance methods.
Author T.Y. is an Associate Editor of Digestive Endoscopy and T.Y. receives research grants from Fujifilm and Olympus outside of this work. T.K. declares no conflict of interest for this article.
期刊介绍:
Digestive Endoscopy (DEN) is the official journal of the Japan Gastroenterological Endoscopy Society, the Asian Pacific Society for Digestive Endoscopy and the World Endoscopy Organization. Digestive Endoscopy serves as a medium for presenting original articles that offer significant contributions to knowledge in the broad field of endoscopy. The Journal also includes Reviews, Original Articles, How I Do It, Case Reports (only of exceptional interest and novelty are accepted), Letters, Techniques and Images, abstracts and news items that may be of interest to endoscopists.